Abstract |
(-)-(S)- Bromofosfamide ((2S)-(2-chloroethylamino)-3-(2-bromoethyl)-1,3,2-oxazaphosphorinane 2-oxide, CAS 146452-37-1, CBM-11) is a new potential anti- cancer drug, currently under investigation. Its pharmacokinetics and bioavailability were studied in female mice following intravenous and oral administration of the dose of 50 mg/kg. The compound was extracted from plasma samples using chloroform and analyzed by high-performance liquid chromatography with UV detection at 200 nm. Orally administered (-)-(S)- bromofosfamide was absorbed quickly, attaining a maximum level of 33.9 micrograms/ml at 5 min, and was eliminated with a half-life (t1/2) of about 0.9 h. The average half-life of intravenously administered (-)-(S)- bromofosfamide was about 0.7 h. The total plasma clearance (CL) and volume of distribution (Vd) were found to be 0.14 l/h and 4.92 l/kg, respectively. The absolute bioavailability of (-)-(S)- bromofosfamide after oral administration was 105%.
|
Authors | K Kobylińska, M Kobylińska, B Sobik |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 51
Issue 7
Pg. 596-9
( 2001)
ISSN: 0004-4172 [Print] Germany |
PMID | 11505792
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- bromofosfamide
- Ifosfamide
|
Topics |
- Administration, Oral
- Animals
- Antineoplastic Agents, Alkylating
(administration & dosage, pharmacokinetics)
- Area Under Curve
- Biological Availability
- Chromatography, High Pressure Liquid
- Female
- Half-Life
- Ifosfamide
(administration & dosage, analogs & derivatives, pharmacokinetics)
- Injections, Intravenous
- Mice
- Spectrophotometry, Ultraviolet
|